CMPX Latest Press Releases

-- October 24, 2026 --

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 Globe Newswire 4:15 AM

-- October 14, 2026 --

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- September 22, 2026 --

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback Globe Newswire 8:30 AM

-- August 6, 2026 --

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- July 17, 2026 --

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 Globe Newswire 10:42 AM

-- June 30, 2026 --

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PRNewswire 9:00 AM

-- June 12, 2026 --

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell Globe Newswire 8:10 AM

-- May 28, 2026 --

Compass Therapeutics to Participate in Upcoming June Investor Events Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes